Roche culls development of two Huntington’s disease programmes

These two programme terminations leave Roche with just one Huntington’s disease candidate, a gene therapy called RG6662. These two programme terminations leave Roche with just one Huntington’s disease candidate. Roche said that the programmes have not been dropped due to any safety concerns. Credit: Marlon Trottmann / Shutterstock.com Roche has stopped development of two of its Huntington’s disease candidates after one failed to show benefit in a Phase II trial and another showed concerns around chronic administration. As a result, the Swiss pharma is discontinuing the clinical programmes for both tominersen and RG6496. Huntington’s Disease Opportunity Assessment and Forecast…

Source: Clinical Trials Arena